Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report

Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report

Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a KIT exon 11 deletion and amplification. The patient exhibi...

Full description

Bibliographic Details
Main Authors: Masahiro Torasawa, MD, Tatsuya Yoshida, MD, PhD, Kouya Shiraishi, PhD, Naoko Goto, BS, Toshihide Ueno, PhD, Hitoshi Ichikawa, MD, PhD, Shigehiro Yagishita, MD, PhD, Shinji Kohsaka, MD, PhD, Yasushi Goto, MD, PhD, Yasushi Yatabe, MD, PhD, Akinobu Hamada, PhD, Hiroyuki Mano, MD, PhD, Yuichiro Ohe, MD, PhD
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:JTO Clinical and Research Reports
Subjects:
Case report
Thymic carcinoma
Lenvatinib
Disease flare
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324000274

Internet

http://www.sciencedirect.com/science/article/pii/S2666364324000274

Similar Items